Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 4—April 2026

Research

Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance

Elif Karaaslan, Amy Whitesell, Jason Malenfant, William C. Carson, Michael Townsend, Kasongo Kayembe Jolie, Enogo Koivogui, Siba Michel Grovogui, Boubacar Diallo, Nouonan Gbamou, Salomon Corvil, Sanaba Boumbaly, Lise Martel, Julie R. Sinclair, Alimou Camara, Trevor Shoemaker, Mary J. Choi, Joel M. Montgomery, Christina F. Spiropoulou, and Éric BergeronComments to Author 
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Karaaslan, A. Whitesell, J. Malenfant, W.C. Carson, M. Townsend, L. Martel, J.R. Sinclair, T. Shoemaker, M.J. Choi, J.M. Montgomery, C.T. Spiropoulou, É. Bergeron); African Field Epidemiology Network, Conakry, Guinea (K.K. Jolie, S. Corvil); Ministry of Health, Conakry (E. Koivogui, S.M. Grovogui); US Centers for Disease Control and Prevention, Conakry (B. Diallo); Agence Nationale de Sécurité Sanitaire, Conakry (N. Gbamou); International Center for Research of Tropical Infections in Guinea, N’Zerekore, Guinea (S. Boumbaly); Ministry of Higher Education, Scientific Research, and Innovation, Conakry (A. Camara); University of Georgia, Athens, Georgia, USA (É. Bergeron).

Main Article

Figure 3

Kinetics of antibody responses in ERVEBO vaccinees for study of development of multiplex assay to confirm Ebola vaccination. US vaccinees who received 1 dose of ERVEBO vaccine were grouped into time intervals of <6 months, 6–12 months, and >12 months postvaccination, and changes in median MFI signal over time were evaluated. A) Ebola virus (EBOV) glycoprotein (GP) 1,2; B) EBOV secreted GP; C) vesicular stomatitis virus nucleoprotein N-terminally fused with P peptide. The scatter plots represent readings from each sample; horizontal solid lines represent group medians, and horizontal dotted lines represent the cutoff for the given protein. The empty squares, triangles, and circle represent samples from 3 vaccinees that were not detected with EBOV GP1,2. Figure created using BioRender (https://www.biorender.com). MFI, mean fluorescence intensity.

Figure 3. Kinetics of antibody responses in ERVEBO vaccinees for study of development of multiplex assay to confirm Ebola vaccination. US vaccinees who received 1 dose of ERVEBO vaccine were grouped into time intervals of <6 months, 6–12 months, and >12 months postvaccination, and changes in median MFI signal over time were evaluated. A) Ebola virus (EBOV) glycoprotein (GP) 1,2; B) EBOV secreted GP; C) vesicular stomatitis virus nucleoprotein N-terminally fused with P peptide. The scatter plots represent readings from each sample; horizontal solid lines represent group medians, and horizontal dotted lines represent the cutoff for the given protein. The empty squares, triangles, and circle represent samples from 3 vaccinees that were not detected with EBOV GP1,2. Figure created using BioRender (https://www.biorender.com). MFI, mean fluorescence intensity.

Main Article

Page created: March 04, 2026
Page updated: March 30, 2026
Page reviewed: March 30, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external